SARS-CoV-2 pneumonia n = 566 | Influenza pneumonia n = 481 | |||||
---|---|---|---|---|---|---|
No putative IPA, or colonization (n = 543) | Aspergillus colonization (n = 9) | Putative IPA (n = 14) | No putative IPA, or colonization (n = 432) | Aspergillus colonization (n = 20) | Putative IPA (n = 29) | |
Prone positioning | 363/543 (66.9) | 6/8 (75.0) | 12/14 (85.7) | 126/432 (29.2) | 8/19 (42.1) | 17/29 (58.6) |
ECMO | 58/542 (10.7) | 0/9 (0.0) | 2/14 (14.3) | 49/432 (11.3) | 5/19 (26.3) | 6/28 (21.4) |
Ventilator-associated lower respiratory tract infections | 271/543 (49.9) | 7/9 (77.8) | 7/14 (50.0) | 127/432 (29.4) | 7/20 (35.0) | 12/29 (41.4) |
Antimicrobial treatment duration, days† | 12 (7 to 18) | 16 (10 to 19) | 18 (8 to 20) | 9 (6 to 16) | 21 (12 to 28) | 17 (9 to 27) |
Corticosteroids | 188/517 (36.4) | 3/9 (33.3) | 10/14 (71.4) | 161/426 (37.8) | 8/20 (40.0) | 12/28 (42.9) |
Hydrocortisone | 55/512 (10.7) | 2/9 (22.2) | 2/14 (14.3) | 92/424 (21.7) | 7/20 (35.0) | 7/28 (25.0) |
Dexamethasone | 44/512 (8.6) | 0/9 (0.0) | 4/14 (28.6) | 1/424 (0.2) | 0/20 (0.0) | 0/28 (0.0) |
Methylprednisolone | 85/512 (16.6) | 1/9 (11.1) | 4/14 (28.6) | 67/424 (15.8) | 1/20 (5.0) | 5/28 (17.9) |
Highest daily dose, mg‡ | 100 (50 to 133) | 50 (50 to 100) | 100 (50 to 133) | 50 (50 to 100) | 50 (50 to 100) | 63 (50 to 100) |
28-day outcomes | ||||||
Mechanical ventilation duration, days | 14 (8 to 22) | 23 (12 to 28) | 23 (17 to 28) | 9 (5 to 18) | 24 (11 to 28) | 21 (12 to 28) |
Ventilator-free days | 6 (0 to 16) | 0 (0 to 0) | 1 (0 to 2) | 13 (0 to 21) | 1 (0 to 12) | 0 (0 to 3) |
ICU length of stay, days | 17 (12 to 27) | 28 (13 to 28) | 25 (19 to 28) | 13 (8 to 25) | 28 (17 to 28) | 25 (15 to 28) |
ICU-free days | 0 (0 to 12) | 0 (0 to 0) | 0 (0 to 0) | 5 (0 to 18) | 0 (0 to 2) | 0 (0 to 0) |
ICU mortality | 154/543 (28.4) | 4/9 (44.4) | 5/14 (35.7) | 111/432 (25.7) | 3/20 (15.0) | 11/29 (37.9) |
28-day mortality | 156/543 (28.7) | 4/9 (44.4) | 5/14 (35.7) | 118/432 (27.3) | 3/20 (15.0) | 11/29 (37.9) |